France, Italy and Belgium have taken measures to eliminate the use of protivokrazhnogo of hydroxychloroquine for the treatment of patients with coronavirus infection. The decision to refuse from the use of the drug was taken due to security problems, writes Reuters.
So, France has cancelled a decree according to which working in hospitals, doctors could prescribe hydroxychloroquine patients, and the Italian and Belgian regulators have suspended the permission to use the drug outside of clinical trials. The Supervisory authorities of Belgium emphasized that ongoing clinical trials will also be appreciated the potential risks of the drug.
In an article published in The Lancet, says that patients treated with hydroxychloroquine, it was observed an increased risk of death and heart rhythm disturbances. European regulators concluded that the identified risks and insufficient evidence of efficacy is not evidence in favor of its use in broad populations of patients with coronavirus.